Head biotechs with good business continue to be optimistic about maintaining the "overweight" rating of these pharmaceutical companies

[Pharmaceutical Network Market Analysis] According to institutional analysis, with the accelerated approval of innovative drugs; the rapid increase in product volume; the approval of overseas authorization of innovative drugs, etc.
, leading biotechs with good business will continue to be optimistic
.

The agency believes that the domestic drug market structure is expected to be further adjusted, leaving sufficient development space for domestic innovative drugs; and overseas markets are expected to gradually reflect China's status as a major country, represented by BeiGene zanubrutinib and legendary bio-cilta-cel Domestic innovative drugs are expected to achieve rapid growth overseas; in addition, the head biotech has sufficient catalysts in the future and is expected to achieve sustained and rapid growth
.

Maintain the "overweight" rating of BeiGene, Cinda Bio, Rongchang Bio, Nuocheng Jianhua, and Keji Pharmaceutical
.

It is understood that BeiGene is a global, commercial-stage biotechnology company focusing on the research, development, production and commercialization of innovative drugs.
(anti-PD-1 monoclonal antibody), pamiparib
.

The company's independent research and development product BRUKINSA (Baiyueze) has achieved a breakthrough in China's original research and new drugs going overseas
.

Data show that in 2021, BeiGene's operating income will increase by 280.
83% year-on-year to US$1.
176 billion
.

 　　Innovent Bio has successfully established a product chain with 29 high-value products and expanded to 32 as of the announcement date of the annual report, covering a series of proven innovative targets and drug forms by virtue of its comprehensive integration platform and strategic partnership.
, including monoclonal antibodies, bispecific antibodies, fusion proteins, CAR-T and small molecule drugs, covering multiple disease areas including oncology, metabolism, immunology and ophthalmology
.

The data shows that in 2021, Innovent's total revenue will increase by 74.
1% year-on-year to 4.
261 billion yuan; of which sales revenue from products will increase by 69% year-on-year to 4.
001 billion yuan
.

 　　The industry said that they are increasingly optimistic about the growth prospects of Innovent Bio.
On the one hand, it stems from a year-on-year increase of about 70% in product sales last year.
On the other hand, Innovent Bio is expanding its partnership with Eli Lilly (LLY.
US).
relationship
.

It is expected that Innovent will launch two other lower-risk products by the end of this year.
It is reported that in addition to Tyvyt, its R&D pipeline will have progress in many products, including the submission of 3 new drug marketing applications and 4 registrations.
clinical trials
.

 　　For Nuocheng Jianhua, some institutions said that its R&D and commercialization capabilities have been initially recognized, various businesses have begun to circulate, the overall cash reserves are abundant, and the short-term demand for external financing is low
.

 　　It is understood that Nuocheng Jianhua has built an integrated biopharmaceutical platform, taking into account the needs of R&D quality and R&D speed, and has established a product pipeline with a high degree of balance between innovation and risk, covering multiple hot targets with market prospects
.

Among them, in addition to the approval of two indications for orelabrutinib, six other indications are in the registration trial stage in China and the United States
.

In addition, there are nine products in clinical stage, many products in preclinical stage, and more than 30 clinical trials are underway around the world
.

 　　For Rongchang Biotechnology, some institutions pointed out that three aspects are mainly considered: the competitive advantages of the three major varieties, the preliminary commercialization results and the broad market space at home and abroad; three technology platforms have been built, covering antibodies and fusion proteins, ADC, double antibody , can continue to expand the pipeline in the three major fields of autoimmunity, oncology and ophthalmology, and promote the company's long-term development; the excellent resume of the management further empowers the company's development
.

 　　As an innovative biopharmaceutical company, Keji Pharmaceutical mainly focuses on innovative CAR-T cell therapy for the treatment of hematological and solid tumors
.

It is reported that Keji Pharmaceutical has established 12 innovative candidate product pipelines.
Through the dual-line layout, the company has continued to advance in the fields of hematological tumors and solid tumors, and has made positive progress
.

In addition, Keji Pharmaceutical has continued to increase investment in research and development, which has laid a solid foundation for its technical strength in the industry
.

Judging from Keji Pharmaceutical's annual performance announcement, in 2021, Keji Pharmaceutical's R&D investment will be 502 million yuan
.

With the support of continuous R&D investment, Keji Pharmaceutical has not only achieved a comprehensive acceleration of the R&D process of core products, but also developed related technologies that are conducive to the development of cell therapy in the process of R&D exploration
.

According to the industry, among a number of innovative pharmaceutical companies, Keji Pharmaceutical has shown the potential for outbreaks
.

 　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.